Use the Back button in your browser to see the other results of your search or to select another record.
| Effect of median nerve neural mobilisation and cervical lateral glide on pain, disability and function in patients with nerve-related neck and arm pain: a systematic review and meta-analysis |
| Gillot T, Lefebvre D, Michalak A, Miossec L, Combret Y, Prum G |
| Clinical Rehabilitation 2025 Nov;39(11):1405-1424 |
| systematic review |
|
OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the effects of cervical lateral glide and median nerve neural mobilisation compared to no treatment and other physical therapy treatments on pain, function and disability in patients with nerve-related neck and arm pain. DATA SOURCES: Electronic searches were conducted in MEDLINE, Science Direct, Cochrane Library, PEDro and Google Scholar up to 30 June 2025. REVIEW METHODS: Randomised controlled trials were included following PRISMA guidelines. Two authors independently selected relevant studies, extracted data, assessed risk of bias (RoB2 tool), and rated evidence quality. Meta-analysis was performed using random-effects models due to expected heterogeneity. The study was registered on PROSPERO (CRD42020216739). RESULTS: Overall, 20 studies with 953 patients met the inclusion criteria. Cervical lateral glide reduced pain compared to no treatment (3 studies, MD -2.47; 95% CI -3.41 to -1.53; p < 0.001) and other physical therapy techniques (2 studies, MD -1.29; 95% CI -2.54 to -0.05; p = 0.04). Median nerve neural mobilisation also reduced pain compared to no treatment (4 studies, MD -3.07; 95% CI -3.78 to -2.37; p < 0.001). Both interventions had modest effects on disability (12 studies, SMD -0.50 to -1.22), with moderate-to-high heterogeneity in analyses. The certainty of evidence was low to very low. CONCLUSION: Cervical lateral glide and median nerve neural mobilisation are clinically effective for reducing nerve-related neck and arm pain as part of multimodal management strategies. The quality of evidence remains low as the level of certainty. Targeting a population with a clear nociceptive, increased neural mechanosensitivity or neuropathic component should lead to better clinical outcomes.
|